NTRP uses 20th century protocol because the drug works on EVERYONE and at least we've actually seen the details of our FDA protocol. We don't have to slice and dice our patient population into APOE groups. We don't have to slice off parts of the population that might not react to other drug factors and limit our population like some do. We don't have to monitor gut enzymes. It all sounds fancy and impressive to investors I'm sure, but when it works on everyone, why wait 2 years for "analysis"? No one has ever explained that one to me. That was my red flag.
I see AVXL put out another PR yesterday that shows they think their data is SLOWING cognitive decline in a very low "N". Bravo. Also noticed NOWHERE in their slides did it say ANYTHING about any AD readouts this year. Of course that backs up the fact the CEO said that very clearly in a presentation a month or so back as well. He actually said a couple of years just as the FDA trial data base shows.
If a 15 person, 7 week ADULT Rett trial readout is the biggest excitement, I would research Neuren who is about 2 years past that point. As for PDD, who really knows. I wish that well too and hopes it helps someone down the line.
News 
Market Data 
Discover 
